The New York Times on Monday drew attention to the boatload of cash that venture capitalists are bestowing on medical device companies lat...

Israeli biotech is bursting with ideas—or so IN VIVO Blog discovered at the country’s annual biotech fest in Tel Aviv, ILSI Biomed Israel 2...

Sometimes history doesn’t repeat itself. When the Blue Cross Blue Shield Association awarded the lucrative Federal Employee Program pharmacy...

Tomorrow is a big day for Sanofi-Aventis’ fat-buster rimonabant. FDA’s Endocrine and Metabolic Drugs Advisory Committee will scrutinize whet...

GlaxoSmithKline is about to find out whether the phrase " oily discharge " sounds better over-the-counter than it does by prescri...

We hear the onion rings are great So what else happened (didn't happen?) this weekend? A few stories below that IN VIVO Blog picked u...

It was always a question of when, not if. Amgen needed to do something to provide for its post-EPO future; now the action has started. Today...

Last week both Biogen Idec and Genzyme announced significant share buybacks. Wall Street was happy. Biogen is buying back $3 billion worth o...

PhRMA's second Office of Accountability report on DTC advertising is out today (covering the second half of 2006) and, well, nobody is ...

The late Michael Sorrel, one of biotech’s most perspicacious analysts, had a few basic rules for investing, one of which was the call option...